

Implementing and Sustaining Enhanced Recovery After Cesarean (ERAC) in Care



Advancing ob-gyn care for all.

Before We Get Started



This webinar will be recorded



If you need help during the call, please chat an ACOG staff member



Submit your questions throughout this session using the Q&A box



Any questions following this webinar can be sent to alliance@acog.org

Introducing...

THE ALLIANCE FOR


**Clinical Excellence in
Obstetrics and Gynecology**

A New Partner in Quality and Patient Safety

Combining ACOG's trusted expertise with real-world support to help hospitals and health systems deliver safer, more equitable care.

- Evidence-based quality improvement strategies
- Plan to support review of patient safety work
- Tailored support for frontline teams
- Designed for measurable impact

Let's improve ob-gyn care—together.




LAUNCHING
JANUARY 2026

THE ALLIANCE FOR
**Clinical Excellence in
Obstetrics and Gynecology**

An ACOG Foundation Patient Safety Organization


December Sessions



**Intrapartum Fetal Heart
Rate Monitoring:
Interpretation and
Management, ACOG CPG
#10**

December 1, 2025
1:15-2:00pm ET

Conversation



**The Joint Commission PC-06
Unexpected complications in
term newborns**

December 10, 2025
1:00-2:15pm ET

Lecture

Today's Speakers



Dr. Pervez Sultan, MBChB, FRCA, MD (Res)



Dr. Gregg Nelson, MD, PhD, FRCSC

Enhanced Recovery after Cesarean Delivery

Pervez Sultan MBChB, FRCA, MD (Res)

Professor

Department of Anesthesiology, Perioperative and Pain Medicine

Stanford University School of Medicine



Disclaimer

- No relevant financial disclosures



Content

ERAS Society
cesarean delivery
guidelines:
2025 update

Patient-reported
outcome
measures


Core outcome set
for ERAS for CD

Enhanced Recovery

Individual Clinician Anesthesia and Surgical Management













Standardize evidence-based Multimodal Recovery Protocol



Colorectal ERAS 1995
Lancet 1995; 345:763764

OB ERAC 2013
Int J Obstet Anesth. 2013; 22:92-5

ERAS Guidelines for Cesarean Delivery

		Obstetricians	Anesthesiologists	Nurses	Patients
	ERAS Society 1, 2, 3	✓ 	✓ 		
	SOAP consensus statement		✓ 		
	Canadian pathway	✓ (SOGC) 	✓ (CAS) 	✓ 	✓ 

SUMMARY

- Lack of US specific guidelines
- Lack of representation from diverse groups
- Lack of stakeholders from key professional societies

Am J Obstet Gynecol. 2018 Dec;219(6):523.e1-523.e15

Am J Obstet Gynecol. 2018 Dec;219(6):533-544

Am J Obstet Gynecol. 2019 Sep;221(3):247.e1-247.e9

Anesth Analg. 2021 May 1;132(5):1362-1377


Healthcare excellence Canada. 2022

Multidisciplinary ERAS Guidelines

Modified Delphi approach (n=19):

		<ul style="list-style-type: none"> • Lactation consultant • Physical therapist

Diverse group of patient representatives



AJOG
FOR AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY

Cesarean

- 32 interventions:
- 6 Preoperative
 - 13 Intraoperative
 - 13 Postoperative

Wilson RD et al. 2025. Am J Obstet Gynecol
 Caughey AB et al. 2025. Am J Obstet Gynecol
 Sultan P et al. 2025. Am J Obstet Gynecol

Preoperative Interventions

	Intervention	Details	Why?
Nutrition	Limit fasting interval	Solids – 6-8 h Clear fluids - 2 h	↓ Hypovolemia ↓ Metabolic stress ↓ Ketosis
	Carbohydrate loading	Gatorade 32 oz - 2 h (apple juice 16 oz)	↓ Hypoglycemia ↓ Metabolic stress
Education	Patient / <u>staff education</u>	Handout / videos e.g., ‘what to expect’	Set expectations ✓ ↑ Compliance ↓ Anxiety and pain
	Lactation preparation	Handout / prenatal classes Resources / groups	↑ Breastfeeding success: ↑ maternal-neonatal bonding ↓ infection and ↓ SIDS
Optimization	Hb optimization Smoking cessation Exercise / BP / glucose	Screening for anemia Fe tx or Investigations	↓ Postpartum anemia ↓ Fatigue and depression ↓ Perinatal mortality

Intraoperative Interventions

Prevention and treatment of spinal hypotension



PHENYLEPHRINE
Strength _____ mg/mL
Exp. Dt./Tm. _____



Warming

Anti-emetics



Ondansetron Dexamethasone _____ mg/ml
Date _____ Time _____ Int. _____

- Support person
- Vaginal preparation
- Prevention of spinal induced hypotension
 - Crystalloid co-load and phenylephrine
- Maintain maternal / neonatal normothermia
- Optimized uterotonic administration
- Antibiotic prophylaxis
- Intra and postoperative N&V prophylaxis
- Multimodal analgesia initiation
- Promotion of breastfeeding and maternal-newborn bonding
- Intravenous fluid optimization – euvoemia

Uterotonics

OXYTOCIN

Antibiotics



Multimodal analgesia

MORPHINE

Strength _____ mg/mL
Exp. Dt./Tm. _____




Postoperative Interventions

'DREAMS'
(Drinking, Eating, Analgesia, Mobilizing and Sleeping)

- Comfort:**
- Discontinue IV fluids
 - Early oral intake
 - Multimodal analgesia
 - Early catheter removal
 - Promote rest

- VTE prevention:**
- Early mobilization
 - 0-8 h sit on edge of bed, t/f to chair
 - 8-24 h walk 1-2 times in hall
 - 24-48 h walk ≥ 3 times in hall (and aim out of bed for 8 h)
 - Venous thromboembolism prophylaxis



Maternal satisfaction:

- Facilitate patient centric transition to discharge

Breastfeeding support

Return of bowel function


Scheduled: acetaminophen & ibuprofen
As required: opioid e.g., oxycodone

Hematology:

- Anemia remediation
- Glycemic control

Evidence Surrounding ERAC

- 12 studies (n=17,607)
 - Length of hospital stay (MD -0.51 days)
 - Time first mobilization (MD -11.05 h)
 - Time urinary catheter removal (MD -13.19 h)
 - Opioid consumption (MD -21.85 mg MMEq)
 - Cost savings: 3 studies
 - No difference in maternal readmission rates
- Low / Very-low levels of evidence
 - Inconsistent interventions (42) & outcomes (90)
 - Many interventions are strongly recommended given low risk of harm and high chance of benefit



ERAS implementation study is urgently needed to improve levels of evidence

Aspiration: Cluster randomization across CMQCC

Sultan et al. ACCPM 2021;40:100935

Sultan et al. Int J Obstet Anesth 2020;43:72-86

Patient-Reported Outcome Measures (PROMs)



Definition: a survey instrument which evaluates multiple domains of health



PROMs are the **gold standard** for measuring postoperative and postpartum recovery



Invaluable **Quality Improvement** tools:
Benchmarking and incentives

JAMA Netw Open. 2020 May 1;3(5):e205540

JAMA Netw Open. 2021 May 3;4(5):e2111600




Anaesthesia. 2020;75 (Suppl. 1):e143-e150




Health Services and Delivery Research. 2014;2(1):1-89

ObsQoR-10

Obstetric Quality of Recovery Score

- Adapted from QoR-40
 - Removed GA items
 - Added NA items
 - Added in obstetric / baby items
- Scored 0 – 100
 - 0=worst; 100=best recovery
- Implementation at LPCH
 - Anesthesia called if score <65
 - May need OB / lactation / nursing / psych input

		 Worst Imaginable  Moderate  None											
		10	9	8	7	6	5	4	3	2	1	0	
1	Pain								X				7
2	Nausea or vomiting										X		9
3	Dizziness											X	10
4	Shivering										X		9

		 No / Never  Sometimes / with help  Yes / Always											
		0	1	2	3	4	5	6	7	8	9	10	
5	I have been comfortable	0	1	2	3	4	5	6	X	8	9	10	7
6	I am able to mobilise independently	0	1	X	3	4	5	6	7	8	9	10	2
7	I can hold a baby without assistance	0	1	2	X	4	5	6	7	8	9	10	3
8	I can feed / nurse my baby without assistance	0	X	2	3	4	5	6	7	8	9	10	1
9	I can look after my personal hygiene / toilet	0	1	2	X	4	5	6	7	8	9	10	3
10	I feel in control	0	1	X	3	4	5	6	7	8	9	10	2

Sharawi. *Anaesthesia* 2019;74(11):1439-1455

Ciechanowicz. *Br J Anaesth* 2018;122:69–78

Ciechanowicz. *IJOA* 2019;39:51–9

Sultan. *J Clin Anesth.* 2020;63:109781

Sultan. *AJOG:MFM* 2020;2(4):100202

Sultan. *Curr Opin Obstet Gynecol.* 2021;33(2):86-93

ObsQoR – UK and US validation studies

Journal Reference	Delivery type Country	N	Good vs. poor	LOS	EBL	Anti-emetic	Other measures of validity
<i>Brit J Anaes</i> 2019;122(1):69-78	Elective CD GB	100	✓	✓	NA	NA	Elective > Emergency cesarean
<i>Int J Obstet Anesth</i> 2019;39:51-59	Emergency CD GB	100	✓	✓	X	NA	
<i>J Clin Anes</i> 2020;63:109781	Instrumental & SVD GB	123	NA	✓	✓	✓	SVD > Instrumental
<i>AJOG:MFM</i> 2020;2(4):100202	All delivery modes US	215	NA	✓	✓ (Tx)	✓	SVD > cesarean


Validation of Translated Versions of ObsQoR-10

ObsQoR-10 Language	Country	Developed version?	Published / completed / Study underway?
Portuguese	BR	✓	2022. ACCPM
Turkish	TR	✓	2022. Turk J Anesth
Japanese	JP	✓	2023. AJOG Global reports
French	FR	✓	2023. BJA Open
Spanish	CO	✓	2024. BJA Open
Mandarin	SG	✓	2024. Bali J Anaesthesiology
Hebrew	IL	✓	2023. J Clin Anes
Arabic	SA	✓	2022. Saudi J Anesth
German	DE & AT	✓	2025, Int J Obstet Anesth
Filipino	PH	✓	2024. Philippine J Anesthesiol

Inpatient recovery – CD vs SVD

JP

- Observational cohort study
- N=98 (50 elective CD; 48 SVD)
- Nulliparous



	CD	SVD
First analgesia (min)*	333	596
Antiemetics (48 h)*	↑	
Opioids (48h)*	↑	
Max pain 24 h	5.3	5.2
First fluid (min)*	409	109
First food (h)*	25	3.62
Frist walk (min)*	7.9	5.1
Foley removal (h)	23.8	16.5
Discharge (day)*	6	5

Summary

- Post CD recovery largely achieved @ D3 (D2 SVD)
- Pain scores similar up to 24 h postpartum

A Multicenter Evaluation of Quality of Recovery Following Cesarean Delivery

Aims

Evaluate the quality of postpartum recovery across the UK



Predict women with prolonged length of stay



Predict women with a complicated recovery

Methods

ObsQoR at day 1

EQ-5D, complications and readmission at day 30



107 centers



n=1631 postpartum women




Results

Median Length of Stay 39.3 hrs

Median ObsQoR Score

- with vs. without prolonged LOS
- 63.3 vs. 71.7; $p < 0.001$



5.4% readmission rate

Median ObsQoR Score

- with vs. without readmission
- 66.6 vs. 71.5; $p = 0.047$



19.7% Complicated recovery rate

Median ObsQoR Score



- with vs. without readmission/investigations
- 68.9 vs. 71.8; $p = 0.033$





ERAS Society guidelines for Cesarean & Core Outcome Measures to Evaluate ERAC

ERAS - recommended by professional societies (SOAP and ERAS Society)



General measures	
Length of hospital stay	
Pathway or bundle compliance	
Maternal Outcomes	
Maternal satisfaction with analgesia	
Postpartum opioid use (Mg Morphine Equivalents)	
Postpartum opioid use (%)	
Postpartum nausea or vomiting (%)	
Maternal hospital re-admission rate (%)	
Maternal re-attendance rate (unplanned outpatient visit)	
*Obstetric Quality of Recovery-10 score (composite score)	

Process metrics	
Duration of preoperative fasting (liquids)	
Time to first fluid intake postoperatively	
Time to first solid food intake postoperatively	
Time to first mobilization	
Time to urinary catheter removal	
Neonatal related outcomes	
Breastfeeding by time of discharge (%)	

Future steps:

- ERAS toolkit – implementation study

*Wilson RD et al. AJOG 2025. Online in print
 Caughey AB et al. AJOG 2025 Online in print
 Sultan P et al. AJOG 2025 Online in print
 Sultan et al. Anesthesiology 2022;137(2):201-211*

Implementing and Sustaining Enhanced Recovery After Cesarean (ERAC) in Care

Gregg Nelson MD PhD FRCSC

Professor and Deputy Head

Department of Obstetrics & Gynecology

University of Calgary

Calgary, Alberta



Advancing ob-gyn care for all.

Disclosures

- Speaker Fee: Intuitive (2024)
- Advisory Board: Integra Life Sciences (2024)
- Chair Scientific Committee, ERAS Society (unpaid)

Objectives

- Describe the history and current state of ERAS Guidelines in Cesarean Delivery
- Discuss key steps required to start a successful ERAS Cesarean Delivery program at your institution



2000's

Group of European surgeons start to question evidence behind historical practices such as “NPO after midnight”



- *Non-profit Multi-professional Multi-disciplinary Medical Society*
- **Mission statement: Enhancing Recovery After/Around Surgery**
- The mission of the Society is to **develop** perioperative care and to **improve** recovery through:
 - education,
 - research,
 - audit and
 - implementation of evidence-based practice

ERAS Society growth in Nov 2025

250+ units in 25+ countries

Global Surgical Quality Improvement Initiative



- More than one Implementation program
- Implementation program running/announced
- ERAS Center in place
- ERAS center in training
- ERAS center discussions

World J Surg
DOI 10.1007/s00268-012-1772-0



**Guidelines for Perioperative Care in Elective Colonic Surgery:
Enhanced Recovery After Surgery (ERAS[®]) Society
Recommendations**

U. O. Gustafsson · M. J. Scott · W. Schwenk · N. Demartines · D. Roulin ·
N. Francis · C. E. McNaught · J. MacFie · A. S. Liberman · M. Soop ·
A. Hill · R. H. Kennedy · D. N. Lobo · K. Fearon · O. Ljungqvist

Colorectal

Pancreas/liver
Cardiac
Urology
Breast
ENT
Bariatric
Gyn
Cesarean
Many more...

erassociety.org


ERAS is
CRAZY!!



**Guidelines for Perioperative Care in Elective Colonic Surgery:
Enhanced Recovery After Surgery (ERAS®) Society
Recommendations**

U. O. Gustafsson · M. J. Scott · W. Schwenk · N. Demartines · D. Roulin ·
N. Francis · C. E. McNaught · J. MacFie · A. S. Liberman · M. Soop ·
A. Hill · R. H. Kennedy · D. N. Lobo · K. Fearon · O. Ljungqvist

Colorectal



What am I
currently
doing?



Original Investigation | Surgery

Enhanced Recovery After Surgery Guidelines and Hospital Length of Stay, Readmission, Complications, and Mortality

A Meta-Analysis of Randomized Clinical Trials

Khara M. Sauro, PhD; Christine Smith, MSc; Seremi Ibadin, MD; Abigail Thomas, MSc; Heather Ganshorn, MLIS; Linda Bakunda, BBA; Bishnu Bajgain, MSc; Steven P. Bisch, MD, MPH; Gregg Nelson, MD, PhD

JAMA Network Open. 2024;7(6):e2417310.

- Hospital length of stay decreased by 1.88 days (95% CI, 0.95-2.81 days; P<.001)
- Risk of complications decreased 29% (RR, 0.71; 95% CI, 0.59-0.87; P<.001)

Figure 2. Meta-Analysis of Hospital Length of Stay






Figure 4. Meta-Analysis of Complications



12000 refs identified
 1493 full texts screened
 495 studies included
 74 RCTs, 21 countries



Dose response relationship between ERAS compliance and outcomes

****key concept****

ERAS[®] Cesarean Delivery Guidelines

Guidelines for antenatal and preoperative care in cesarean delivery: Enhanced Recovery After Surgery Society recommendations (part 1)–2025 update

Guidelines for intraoperative care in cesarean delivery: Enhanced Recovery After Surgery Society recommendations (part 2)–2025 update

Guidelines for postoperative care in cesarean delivery: Enhanced Recovery After Surgery Society recommendations (part 3)–2025 update

Pervez Sultan ¹, David T Monks ², Nadir Sharawi ³, James Bamber ⁴, Danielle M Panelli ⁵, Khara M Sauro ⁶, Prakeshkumar S Shah ⁷, Giulia M Muraca ⁸, Amy Metcalfe ⁹, Stephen L Wood ¹⁰, Caitlin A Jago ¹⁰, Sean Daly ¹¹, Lindsay E A Blake ¹², George A Macones ¹³, Aaron B Caughey ¹⁴, R Douglas Wilson ¹⁰, Gregg Nelson ¹⁵



Preoperative

Intraoperative

Antenatal pathway: OPTIMIZED

Preadmission information, education and counselling (optimized element)	1. Clinical practice should be adapted to whether cesarean delivery is a scheduled surgery.	Very Low	Strong
	2. Cesarean delivery without medical indication should not be recommended without a solid preadmission evaluation of harms and benefits, both for the mother and the fetus.	Very Low	Low-Low

Preoperative pathway: FOCUSED

Preanesthetic medications (focused elements)	1. Antacids should be administered to prevent aspiration pneumonia.	Low	Strong
	2. Preoperative sedation should be avoided for cesarean delivery because of the potential for detrimental effects on the mother and neonate.	Low	Strong
Preoperative bowel preparation (focused element)	1. Oral or mechanical bowel preparation should not be used before cesarean delivery.	High	Strong
Preoperative fasting (focused element)	1. Women should be encouraged to consume clear juice, coffee, or tea with no sugar. 2. A light meal may be offered to women with a scheduled cesarean delivery.	Low	Strong
Preoperative carbohydrate supplementation (focused element)	1. Oral carbohydrate fluid supplementation before cesarean delivery, may be offered to non-obese women.	Low	Weak

Appendix: Preoperative maternal comorbidity optimization (optimized elements)

	1. Maternal obesity (body mass index, >40 kg/m ²) significantly increases risks of maternal and fetal complications. Optimal gestational weight gain management should be used to control their weight during pregnancy. Surgical complexity requires multidisciplinary planning.	High	Strong
	2. Maternal hypertension should be managed. Maternal chronic hypertension has been associated with an increase in the incidence of maternal and fetal complications.	Moderate	Strong
	3. Maternal gestational diabetes mellitus increases the risk for maternal and fetal morbidity. Maternal diabetes should receive timely and effective management during preconception and pregnancy.	Moderate	Strong
	4. Maternal anemia during pregnancy is associated with low birthweight, preterm birth, and increases perioperative morbidity and mortality. The cause of the anemia should be identified and corrected.	Moderate	Strong
	5. Maternal cigarette smoking is associated with adverse reproductive morbidity and should be stopped before or during pregnancy.	Moderate	Strong

Antenatal pathway focused: (focused elements)	1. Intravenous antibiotics should be administered routinely within 60 min before the cesarean delivery skin incision. In all women, a first-generation cephalosporin is recommended; in women in labor or with ruptured membranes, the addition of azithromycin confers additional reduction in postoperative infections.	High	Strong
	2. Chlorhexidine-alcohol is preferred to aqueous povidone-iodine solution for abdominal skin cleansing before cesarean delivery.	Low	Strong
	3. Vaginal preparation with povidine-iodine solution should be considered for the reduction of postcesarean infections.	Moderate	Weak
	4. Regional anesthesia is the preferred method of anesthesia for cesarean delivery as part of an enhanced recovery protocol.	Low	Strong
Prevention of intraoperative hypothermia (focused element)	1. Appropriate patient monitoring is needed to apply warming devices and avoid hypothermia. 2. Forced air warming, intravenous fluid warming, and increasing operating room temperature are all recommended to prevent hypothermia during cesarean delivery.	Low	Strong
	2. Closure of the hysterotomy in 2 layers may be associated with a lower rate of uterine rupture.	Low	Weak
	3. The peritoneum does not need to be closed because closure is not associated with improved outcomes and increases operating room time.	Low	Weak
	4. Laparoscopic tissue, should be performed.	Moderate	Weak
	5. Laparoscopic tissue, should be performed.	Moderate	Weak
Fluid management (focused element)	1. Perioperative and intraoperative euolemia are important factors in patient perioperative care and appear to lead to improved maternal and neonatal outcomes after cesarean delivery.	Low-moderate	Strong

No bowel prep

Carb load

6 and 2 rule

No sedatives

DVT and Anbx prophylaxis

Multimodal PONV prevention

No NG tubes

Keep patient warm

Judicious intraop fluids

Postoperative

Postoperative pathway

Chewing gum after cesarean section (focused element)	Gum chewing appears to be effective and is low risk. It may be a redundant treatment if a policy for early oral intake is being used. However, it should be considered if delayed oral intake is planned.	Low	Weak
Nausea and vomiting	(1) Fluid preloading, the intravenous administration of	Moderate (multiple	Strong

Bottom Line:
How does your current practice compare?
Can you make changes that will improve outcomes?

Early post—cesarean delivery mobilization (focused element)	Early mobilization after cesarean delivery is recommended.	Very low	Weak
Post—cesarean delivery urinary drainage (focused element)	Urinary catheter should be removed immediately after cesarean delivery, if placed during surgery.	Low	Strong
Postoperative/postpartum mother pathway			
Discharge counselling (focused element)	Standardized written discharge instructions should be used to facilitate discharge counselling.	Low	Weak

Key steps to
successful ERAS
implementation





#1

How to create an ERAS Protocol

“We read the Guidelines, what do we do now??”

REVIEW ARTICLE

Enhanced Recovery after Surgery — Evidence and Practice

Kevin M. Elias, M.D.,¹ Mary E. Brindle, M.D., M.P.H.,^{2,3} and Gregg Nelson, M.D., Ph.D.^{2,4}

Table 2. Example Order Set for an Enhanced Recovery after Surgery Protocol.*

Surgical Phase	Example
Preoperative	
Bowel preparation	<ul style="list-style-type: none"> No mechanical bowel preparation If using an oral antibiotic preparation: neomycin 1 g orally + metronidazole 500 mg orally at 1:00 p.m., 2:00 p.m., and 10:00 p.m. day prior to surgery
Modern fasting guidelines	<ul style="list-style-type: none"> Light snack (dry toast and fruit) allowed up to 6 hours prior to the procedure May ingest clear fluids up to 2 hours before procedure
Carbohydrate loading	<ul style="list-style-type: none"> Complex carbohydrate (e.g., maltodextrin) drink 2 hours prior to surgery
Preoperative medications	<ul style="list-style-type: none"> Acetaminophen 1000 mg orally, once Celecoxib or ibuprofen 400 mg orally, once Aprepitant 40 mg orally
VTE prophylaxis	<ul style="list-style-type: none"> Heparin 5000 IU subcutaneously, given preoperatively or after induction Sequential compression devices placed prior to induction of anesthesia
Antimicrobial prophylaxis	<ul style="list-style-type: none"> Bathe or shower with soap the night before surgery Chlorhexidine alcohol for skin cleansing Cefazolin 2 g intravenously before incision (3 g for weight >120 kg) If bowel resection anticipated: cefazolin 2 g intravenously before incision + metronidazole 500 mg intravenously
Intraoperative	
Nausea and vomiting prophylaxis (antiemetics to choose from)	<ul style="list-style-type: none"> Dexamethasone 4 mg intravenously after induction Amisulpride 5 mg intravenously after induction Droperidol 0.625 to 1.25 mg intravenously, end of surgery Ondansetron 4 mg intravenously, end of surgery Promethazine 6.25 to 12.5 mg intravenously, end of surgery
Anesthesia	<ul style="list-style-type: none"> Short-acting anesthetic agents (e.g., sevoflurane or propofol) should be used Opioid-sparing multimodal analgesia techniques (options): <ul style="list-style-type: none"> Bupivacaine with epinephrine at incision site Liposomal bupivacaine 266 mg (20 ml) diluted to at least 180 ml of sterile saline injected at incision site Transversus abdominis plane block or rectus sheath block using bupivacaine with epinephrine
Best surgical practices	<ul style="list-style-type: none"> Avoidance of peritoneal drains and nasogastric tubes
Maintenance of normothermia	<ul style="list-style-type: none"> Use of active warming device and warmed fluids
Fluid therapy	<ul style="list-style-type: none"> Use of lactated ringers as opposed to normal saline Aim for euvolemia (very restrictive or liberal fluid regimens to be avoided) Use of goal-directed fluid therapy where available and in high-risk cases

Postoperative	
Diet	<ul style="list-style-type: none"> Solid diet started postoperative day (POD) 0 Chewing gum after meals three times per day starting on POD 0 Oral nutritional supplement on POD 0 and continue until discharge
Analgesia	<ul style="list-style-type: none"> Acetaminophen 1000 mg orally every 6 hours (should not exceed 4000 mg/24 h from all sources) (start POD 0) Ketorolac 15 mg or ibuprofen 400–600 mg orally every 6 hours (start POD 0) <p>If scheduled acetaminophen/ibuprofen ineffective (or if contraindications):</p> <ul style="list-style-type: none"> Oxycodone 5–10 mg orally every 4 hours as needed Tramadol 100 mg orally every 4 to 6 hours as needed Opioid, intravenously (e.g., hydromorphone 0.5 mg intravenously every 30 minutes as needed) only if orally opioid medications ineffective within 30 minutes Patient controlled analgesia started only if patient requires two doses or more of intravenous opioids in a 24-hour period
Nausea and vomiting prophylaxis	<ul style="list-style-type: none"> Ondansetron 4 mg orally every 6 hours as needed for nausea Prochlorperazine 10 mg intravenously every 6 hours for breakthrough nausea after 30 minutes <p>Ondansetron</p>
Fluid therapy	<ul style="list-style-type: none"> Fluids at 1 ml/kg/hour postoperatively (typical duration 6 to 8 hours) Fluid bolus of 250 to 500 ml for urine output <0.25 ml/kg/hour Peripheral lock IV when patient has 600 ml oral intake
Urinary catheter removal	<ul style="list-style-type: none"> Remove urinary catheters on the day of surgery for MIS, and no later than POD 1 for laparotomy, unless contraindications exist
VTE prophylaxis	<ul style="list-style-type: none"> Low-molecular-weight heparin (e.g., dalteparin 5000 IU subcutaneously daily or equivalent) starting POD 1 Extended prophylaxis for 28 days for all patients undergoing laparotomy for cancer using either direct oral anticoagulant or low-molecular-weight heparin Sequential compression devices while in bed in hospital



#2

Formation of the ERAS Clinical Team



People who will be doing the work:

OBGYN
Anesthesiologist
Nurse
Dietitian
Pharmacist
Physiotherapist
Manager

****Choose people who are passionate about quality improvement****



#3

ERAS Protocol

ERAS Team

We do ERAS!!

Checklist for ERAS program:

ERAS protocol ✓

ERAS team ✓

Audit system ?



Do you audit your
program?

We think we know...
But Audit is the only way to get control
(“we don’t know what we don’t measure”)

How to audit?

Preoperative

*Weight 6 months prior to admission: 80 ? (kg) Unknown

**Preoperative body weight: 70 ? (kg) Unknown

Preoperative weight change:

**Preoperative nutritional status assessment: 2 - Yes, risk of malnutrition ?

*Screening Instrument: 4 - MNA ?

**Preoperative nutritional treatment: 1 - Yes, oral supplements ?

*Height: 160 ? (cm) Unknown

BMI:

**Smoker: 2 - Stopped because of surgery ?

*Termination of smoking (no of weeks before surgery): 4 ? Unknown

**Alcohol usage: 0 - No ?

*Diabetes mellitus: 1 - Yes, on medication ?

*Severe heart disease: No Yes Unknown ?

*Severe pulmonary disease: No Yes Unknown ?

*Last HbA1c value: 7 (%) 53.0 ? (mmol/mol) Unknown

*Preoperative WHO performance score: 1 - Symptomatic, ambulant ?

*Recent immunosuppressive treatment: No Yes Unknown ?

*Preoperative chemotherapy: No Yes Unknown ?

Date of last chemotherapy treatment: 07/03/2016 ? (dd/mm/yyyy) Unknown

Days between admission and the last chemotherapy:

*Any radiotherapy to operating field: No Yes Unknown ?

*Previous surgery to same abdominal region: No Yes Unknown ?

**Preadmission patient education given: No Yes Unknown ?

*Recreational drug use: No Yes Unknown ?

SURGERY

*Operation actually performed: 1 - Yes ?

*Date of primary operation: 07/03/2016 ? (dd/mm/yyyy)

*Mode of surgery: 1 - Elective surgery ?

Primary operator: TSTSURG - Test Test ?

Grade of surgical education:

**Main procedure name: 710 - Debulking ?

Hysterectomy BSO
 BPLNS PALNS
 Infracolic Omentectomy Supracolic Omentectomy
 Appendectomy Large Bowel Resection
 Small Bowel Resection Splenectomy
 Diaphragm stripping Radical Cystectomy
 Urologic diversion

*Additional major procedures: 7 - HIPEC ?

**Surgical approach: 71 - Open ?

Surgical approach group:

*Operation converted: 0 - No ?

*New stoma: 2 - Yes, ileostomy ?

*Bowel anastomosis: 1 - Yes ?

*Type of bowel anastomosis: -Select- ?

*Anastomotic technique: 2 - Circular stapler ?

*Length of incision: 30 ? (cm) Unknown

*Intraoperative blood loss: 500 ? (ml) Unknown

*Start of operation: 08:00 ? (HH:MM, 24 hrs) Unknown

*Stop of operation: 11:15 ? (HH:MM, 24 hrs) Unknown

Length of operation:

*Peritoneal soiling / contamination: 1 - No soiling ?

**Resection-site drainage: No Yes Unknown ?

*Urinary drainage postop: 1 - Urethral catheter ?

ANAESTHESIA

*ASA physical status class: 2 - ASA 2 ?

**Previous PONV or motion sickness: No Yes Unknown ?

**PONV prophylaxis administered: No Yes Unknown ?

*General anaesthesia: 2 - Inhalational (volatiles) ?

*Nitrous oxide used: No Yes Unknown ?

**Systemic opioids given: 1 - Yes, short acting (remifentanyl) ?

*Airway control: 2 - Endo-tracheal tube (ETT) ?

*Depth of anaesthesia monitored: No Yes Unknown ?

**Epidural or spinal anaesthesia: 2 - No, contraindicated ?

*Nerve blocks or local anaesthesia: 3 - Transversus abdominus plane ?

*Infusion of vasoactive drugs: No Yes Unknown ?

**Upper-body forced-air heating cover used: No Yes Unknown ?

*Heated IV fluids used: No Yes Unknown ?

*Core body temperature at end of operation: 37 ? (°C) Unknown

*IV volume of crystalloids intraoperatively: 2000 ? (ml) Unknown

*Use of 0.9% NaCl: No Yes Unknown ?

*IV volume of colloids intraoperatively: ? (ml) Unknown

*IV volume of blood products intraoperatively: 0 ? (ml) Unknown

Total IV volume of fluids intraoperatively:

**Fluid administration guidance: 0 - No guidance ?

**Nasogastric tube used postoperatively: No Yes Unknown ?

Postoperative Data

- Admission Information
 - Patient registration
 - Preoperative data
 - Operation
 - Before surgery
 - Surgery
 - Anaesthesia
 - Recovery
 - Fluid balance
 - GI and stoma function
 - Mobilisation
 - Pain and nausea control
 - Discharge
 - Discharge
 - Complications
 - 30 day followup
 - Final diagnosis
 - 30 day followup
 - Complications after stay
 - P-POSSUM scoring
 - P-POSSUM scoring

COMPLICATIONS AT ALL DURING PRIMARY STAY

*Complications at all during primary stay: No Yes Unknown ?

*Number of nights receiving intensive care: ? Unknown

*Re-operation(s): ?

*Grading of most severe complication: ?

Complication severity grade:

*Respiratory complication(s): No Yes Unknown ?

*Infectious complication(s): No Yes Unknown ?

*Cardiovascular complication(s): No Yes Unknown ?

*Renal, hepatic, pancreatic and gastrointestinal complication(s): No Yes Unknown ?

*Surgical complication(s): No Yes Unknown ?

No

Yes, radiological diagnosis with no intervention

*Anastomotic leak: Yes, drained percutaneously Yes, reoperated Unknown

*Urinary tract injury: No Yes Unknown ?

*Mechanical bowel obstruction: No Yes Unknown ?

*Postoperative paralytic ileus: No Yes Unknown ?

*Deep wound dehiscence: No Yes Unknown ?

*Intraoperative excessive haemorrhage: No Yes Unknown ?

*Postoperative excessive haemorrhage: No Yes Unknown ?

*Other surgical technical complication or injury: No Yes Unknown ?

*Complication(s) related to epidural or spinal anaesthesia: No Yes Unknown ?

*Anaesthetic complication(s): No Yes Unknown ?

ERAS® Interactive Audit System





#4



Putting it all together

“The ERAS Way”


ERAS team meets regularly to review protocol compliance and clinical outcomes (LOS, complications)

Low compliance  High compliance

What do you do with audit data?
(how to achieve change?)

ERAS Compliance Data pre-ERAS 2015

Hospital compliance measure




“Important to see where you are doing well, where you are not doing well, and also where you are not collecting data...”



Putting it all together






“The ERAS Way”

ERAS team meets regularly to review protocol compliance and clinical outcomes (LOS, complications)



Plan-Do-Study-Act cycles = concrete action plans targeted towards areas of low compliance

Successful ERAS Implementation

-  Create an ERAS protocol
-  Create ERAS clinical team
-  Audit baseline compliance and outcomes
-  Team meets regularly, PDSA cycles to increase compliance
-  **Clinical outcomes improved**



All proceeds to the



THE ERAS[®] SOCIETY HANDBOOK FOR
**OBSTETRICS &
GYNECOLOGY**

EDITED BY
GREGG NELSON
PEDRO T. RAMIREZ
SEAN C. DOWDY
R. DOUGLAS WILSON
MICHAEL J. SCOTT

ERAS[®]Society



Conclusions

- ERAS
 - Global surgical quality improvement program changing the course of surgery as we know it
- ERAS Caesarean Guidelines/team/audit system
 - help integrate knowledge into practice
 - align perioperative care
 - improves outcomes for patients

Questions?

Please enter your questions in the Q&A box at the bottom of your screen.

Thank you!

Please send any questions to
alliance@acog.org



Advancing ob-gyn care for all.